Min Zhang
Huiwen Ma2†
Zhongzhen Yuan- 1Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China
- 2Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. This case firstly reported a case of drug-drug interaction between traditional Chinese medicine (TCM) and osimertinib. A 57-year-old female was diagnosed with stage IV lung adenocarcinoma, who switched from gefitinib to osimertinib after disease progression. However, the carcinoembryonic antigen (CEA) results suggested biochemical recurrence after 48 months. The first osimertinib trough concentration (Ctrough) was 82.1 ng/mL, significantly lower than the FDA-reported 166 ng/mL, with concurrent elevation of the tumor marker carcinoembryonic antigen (CEA). After excluding other possible factors, the decreased osimertinib concentration might be due to the TCM taken by the patient. After adjusting the TCM prescription, the patient’s osimertinib Ctrough was stable within the range of 145 and 228 ng/mL without significant adverse reactions and carcinoembryonic antigen levels stabilized. This case underscored the importance of monitoring drug concentrations in patients concurrently using TCM and osimertinib to optimize treatment outcomes and minimize potential drug-drug interactions.
Introduction
Osimertinib, as a third-generation EGFR-TKI, played an important role in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) (Yuan et al., 2022). The United States Food and Drug Administration (FDA) reported osimertinib median trough concentration (Ctrough) was 166 μg/L (Verheijen et al., 2017). However, its exposure was susceptible to the influence of patients’ physiological and pathological conditions and drug-drug interactions (DDIs), resulting in significant inter-individual variability (Boosman et al., 2022). The coefficient of variation for intra-patient pharmacokinetics is 20.8%, while the inter-patient coefficient of variation is 37.5% (Boosman et al., 2022). Since 2016, the National Health Commission of the People’s Republic of China (NHC) encouraged the use of traditional Chinese medicine (TCM) as an important measure to optimize cancer diagnosis and treatment models (Author Anonymous, 2016). TCM had been widely used to enhance immunity, alleviate adverse reactions, and assist anti-tumor treatment in cancer patients (Chen et al., 2015; Li et al., 2022; Yu et al., 2022). It was found that most TCM extracts inhibited CYP450 mediated-metabolism of at least three isozymes (ranging from 25%–100%) (Foster et al., 2002). Osimertinib was primarily metabolized by hepatic CYP3A4/5 enzymes and transported by efflux transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (Yokota et al., 2022). However, due to the complex composition of TCM prescriptions, potential pharmacokinetic and pharmacodynamic interactions existed with concurrently used Western drugs (Li et al., 2022). This article is the first to report a case of drug interaction between TCM and osimertinib, exploring the impact of TCM on osimertinib plasma concentration and treatment effect.
Case description
A 57-year-old female (height: 150 cm, weight: 52 kg) was diagnosed with stage IV (cT2bN0M1a) lung adenocarcinoma harboring an exon 19 deletion of EGFR in March, 2019. After 1 year and 5 months of treatment with gefitinib, the efficacy evaluation indicated progressive disease (PD), as the computed tomography of the chest suggested no significant changes in the pulmonary lesions (showed in Figure 1). The patient’s medication adjustment chart is shown in Figure 2.
Figure 1. The patient’s chest computed tomography (CT) scans.
Figure 2. The patient’s medication adjustment timeline.
The magnetic resonance imaging (MRI) of the head indicated enhancement in the anterior falx of the brain, with metastasis to be ruled out. Due to the presence of the T790M mutation in the blood genetic test, the treatment was adjusted to osimertinib 80 mg once daily in October 2020. During the period from March 2021 to February 2023, the patient exhibited stable disease (SD) (see Figure 1). However, during the regular monitoring of tumor markers, the carcinoembryonic antigen (CEA) showed an abnormal result on 11 February 2023 (19.49 ng/mL), and further increased to 28.24 ng/mL on 21 March 2023, suggesting a biochemical recurrence. The patient refused chemotherapy and, to delay the onset of osimertinib resistance, the patient was recommended increasing the dosage of osimertinib. Increasing the dosage of osimertinib might increase adverse reactions and the economic burden on patients. Osimertinib blood concentration monitoring was recommended, which could also help determine whether elevated CEA levels was related to insufficient drug concentration. Therefore, the patient was recommended taking osimertinib at a fixed time every day, and have their blood drawn half an hour before the next dose to measure the osimertinib Ctrough.
On 29 March 2023, the first osimertinib blood concentration was 82.1 ng/mL, significantly lower than the FDA-reported median Ctrough of 166 ng/mL (Verheijen et al., 2017). The timing of blood sampling and potential testing errors were thoroughly investigated and subsequently excluded as causes. The patient demonstrated high adherence to the protocol (The result was shown in Supplementary Table 1). Liver and renal function tests yielded normal results. The patient did not experience nausea, vomiting, or diarrhea, and gastrointestinal abnormalities were ruled out based on routine stool examination (The result was shown in Supplementary Table 2). Therefore, the decrease in concentration might be related to the TCM prescription used by the patient to treat cough (see Table 1). At the same time, we used the Drug Interaction Probability Scale (DIPS) to evaluate a potential interaction between TCM and Osimertinib (Horn et al., 2007). The result of this case was a score of 5, indicating that the interaction between TCM and osimertinib is probable (The result was shown in Supplementary Table 3). In the TCM prescription, Chishao (Paeonia lactiflora), Ezhu (Curcuma zedoaria), Fuchaobaizhu (Atractylodes macrocephala), Danggui (Angelica sinensis), and Gancaopian (Glycyrrhiza uralensis) might act on P-gp and CYP3A enzymes, thereby affecting the plasma concentration of osimertinib. After communication between the clinical pharmacist and the doctor, the TCM prescription was adjusted and optimized based on the principle of syndrome differentiation and treatment (see Table 2). On 18 April 2023, a follow-up check showed osimertinib blood concentration at 145 ng/mL and CEA at 28.81 ng/mL. CEA showed no further increase, and efficacy was evaluated as SD. In multiple follow-up checks before August 2023, osimertinib blood concentration and CEA remained generally stable, and no significant adverse reactions occurred (see Figure 3).
Table 1. The patient had recently taken traditional Chinese medicine prescription.
Table 2. After optimizing the prescription of Chinese medicine.
Figure 3. Trends of osimertinib blood concentration and carcinoembryonic antigen levels.
Discussion
During the patient’s use of the first TCM prescription, the steady-state Ctrough of osimertinib was 82.1 ng/mL, which might reduce clinical efficacy and subsequently lead to an increase in CEA levels, consistent with previous reports (Verheijen et al., 2017; Yamazaki et al., 2023; Fukuhara et al., 2023). Previous studies have demonstrated that the exposure of multiple tumor-targeting drugs were related to their efficacy and toxicity (Verheijen et al., 2017). A Japanese clinical study found that the median progression-free survival (PFS) was significantly longer in the osimertinib Ctrough ≥211 ng/mL group compared to the Ctrough <211 ng/mL group (Yamazaki et al., 2023). Additionally, a prospective study by Fukuhara et al. (Fukuhara et al., 2023) reported that a median Ctrough of 227 ng/mL for osimertinib, with patients exhibiting Ctrough levels between 164 and 338 ng/mL experiencing longer PFS. Furthermore, osimertinib Ctrough levels exceeding 235 ng/mL were significantly associated with more severe adverse events, which led to treatment discontinuation, dose reduction, and consequently impacted treatment efficacy (Agema et al., 2022).
The Ctrough of Osimertinib significantly increased after modifying the components of the TCM prescription, potentially due to certain herbs in the TCM prescription affecting hepatic enzyme activity. Osimertinib was primarily metabolized by hepatic CYP3A4/5 enzymes and was transported by efflux transporters such as P-gp and BCRP (Yokota et al., 2022). When osimertinib was co-administered with a strong CYP3A4 inhibitor, its area under the curve (AUC) and Cmax increased by 24% and 20%, respectively, compared to administration alone. Conversely, co-administered with a strong CYP3A4 inducer results in decreases of 82% and 78% in AUC and Cmax, respectively (Yokota et al., 2022; Vishwanathan et al., 2018). Numerous studies had demonstrated that TCM could exert varying degrees of inhibitory or inductive effects on the activity of hepatic CYP3A enzymes and P-gp transport (Pao et al., 2012; He et al., 2010; Ioannides, 2002), which might lead to alterations in the systemic exposure of osimertinib (Xu and Li, 2019). St. John’s wort has been shown to induce the expression of CYP3A4 and P-glycoprotein, while milk thistle (Naiji) and grapefruit juice (Putaoyou) could inhibit the activity of CYP3A4 (Ioannides, 2002). Other herbal components that might influence CYP3A activity include ginseng (Renshen), garlic (Dasuan), Danshen (Danshen), and liquorice (Gancao) (Ioannides, 2002). In the first TCM prescription administered to the patient in this case, Paeonia lactiflora (Chishao) might enhance P-gp transport activity, whereas Curcuma phaeocaulis (Ezhu), stir-fried Atractylodes macrocephala (Fuchao Baizhu), Angelica sinensis (Danggui), and Glycyrrhiza uralensis (Gancao) might induce CYP3A enzyme activity (He et al., 2010; Lam et al., 2022; Lv, 2006), potentially leading to a reduction in the plasma concentration of osimertinib. The second TCM prescription eliminated Chishao (P. lactiflora), Ezhu (C. zedoaria), Gancaopian (G. uralensis), while adding Cuwuweizi (Schisandra chinensis), Ganjiang (Zingiber officinale), Renshenpian (Panax ginseng) and Ciwujia (Eleutherococcus senticosus), etc. Notably, Cuwuweizi (S. chinensis) has been shown to inhibit CYP3A enzymes and P-gp transport activity, significantly increasing the exposure of dual P-gp and CYP3A4 substrates, such as tacrolimus (Wu et al., 2016). After using the second TCM prescription, the patient’s osimertinib Ctrough increased compared to the previous levels, and subsequent monitoring revealed that the osimertinib Ctrough remained between 145 and 228 ng/mL. The trends in osimertinib blood concentration were shown in Figure 2, indicating an interaction between the TCM and osimertinib. The patient expressed satisfaction with the current treatment. This case reported the potential interaction between TCM and osimertinib. However, large-scale clinical studies and mechanism researches were needed to further confirm this interaction.
Conclusion
TCM was widely utilized among lung cancer patients in China. However, the interaction between TCM and osimertinib remained unclear. In this case, the patient’s elevated CEA levels were associated with decreased osimertinib concentrations. Following an adjustment to the TCM prescription, osimertinib concentration increased, and the elevated CEA levels were effectively controlled. Our team recommended that osimertinib concentrations be closely monitored in patients concurrently using TCM with osimertinib.
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by The Ethics Committee of Chongqing University Cancer Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
MZ: Supervision, Visualization, Writing – original draft, Writing – review and editing. HM: Data curation, Writing – original draft, Writing – review and editing. WC: Data curation, Funding acquisition, Writing – original draft, Writing – review and editing. ZY: Conceptualization, Data curation, Visualization, Writing – original draft, Writing – review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Chongqing Clinical Pharmacy Key Specialties Construction.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1596913/full#supplementary-material
Refrences
Agema, B. C., Veerman, G. D. M., Steendam, C. M. J., Lanser, D. A. C., Preijers, T., van der Leest, C., et al. (2022). Improving the tolerability of osimertinib by identifying its toxic limit. Ther. Adv. Med. Oncol. 14, 17588359221103212. doi:10.1177/17588359221103212
Author Anonymous (2016). Notice on strengthening standardized diagnosis and treatment management of tumors. Available online at: http://www.nhc.gov.cn/yzygj/s3593/201603/53341b6ab1c14963acceb5d1f37540df.shtml.
Boosman, R. J., Jebbink, M., Veldhuis, W. B., Groenland, S. L., van Veggel, BAMH, Moeskops, P., et al. (2022). Exposure-response analysis of osimertinib in EGFR mutation positive non-small cell lung cancer patients in a real-life setting. Pharm. Res. 39 (10), 2507–2514. doi:10.1007/s11095-022-03355-2
Chen, K. C., Lu, R., Iqbal, U., Hsu, K. C., Chen, B. L., Nguyen, P. A., et al. (2015). Interactions between traditional Chinese medicine and Western drugs in Taiwan: a population-based study. Comput. Methods Programs Biomed. 122 (3), 462–470. doi:10.1016/j.cmpb.2015.09.006
Foster, B. C., Vandenhoek, S., Tang, R., Budzinski, J. W., Krantis, A., and Li, K. Y. (2002). Effect of several Chinese natural health products of human cytochrome P450 metabolism. J. Pharm. Pharm. Sci. 5 (2), 185–189.
Fukuhara, T., Imai, K., Nakagawa, T., Igusa, R., Yokota, H., Watanabe, K., et al. (2023). A prospective cohort study assessing the relationship between plasma levels of osimertinib and treatment efficacy and safety. Biomedicines 11 (9), 2501. doi:10.3390/biomedicines11092501
He, S. M., Yang, A. K., Li, X. T., Du, Y. M., and Zhou, S. F. (2010). Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin. Drug Metab. Toxicol. 6 (10), 1195–1213. doi:10.1517/17425255.2010.510132
Horn, J. R., Hansten, P. D., and Chan, L. N. (2007). Proposal for a new tool to evaluate drug interaction cases. Ann. Pharmacother. 41 (4), 674–680. doi:10.1345/aph.1H423
Ioannides, C. (2002). Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32 (6), 451–478. doi:10.1080/00498250210124147
Lam, C. S., Koon, H. K., Ma, C. T., Au, K. Y., Zuo, Z., Chung, V. C., et al. (2022). Real-world data on herb-drug interactions in oncology: a scoping review of pharmacoepidemiological studies. Phytomedicine 103, 154247. doi:10.1016/j.phymed.2022.154247
Li, C., Jia, W. W., Yang, J. L., Cheng, C., and Olaleye, O. E. (2022). Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines. Acta Pharmacol. Sin. 43 (12), 3080–3095. doi:10.1038/s41401-022-00983-7
Li, D., Han, Y., Yu, Q., and Guo, C. (2010). Progress in the research on the effects of Chinese medicines with different therapeutic effects on cytochrome P450. Chin. Pharm. 21(7): 656–658.
Lv, L. (2006). Review on the effects of Chinese drugs on cytochrome P450. J. Zhejiang Chin. Med. Univ. 3, 315–316.
Pao, L. H., Hu, O. Y., Fan, H. Y., Lin, C. C., Liu, L. C., and Huang, P. W. (2012). Herb-drug interaction of 50 Chinese herbal medicines on CYP3A4 activity in vitro and in vivo. Am. J. Chin. Med. 40 (1), 57–73. doi:10.1142/S0192415X1250005X
Singh, A., and Zhao, K. (2017). Herb-drug interactions of commonly used Chinese medicinal herbs. Int. Rev. Neurobiol. 135, 197–232. doi:10.1016/bs.irn.2017.02.010
Verheijen, R. B., Yu, H., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., and Huitema, A. D. R. (2017). Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin. Pharmacol. Ther. 102 (5), 765–776. doi:10.1002/cpt.787
Vishwanathan, K., Dickinson, P. A., So, K., Thomas, K., Chen, Y. M., De Castro Carpeño, J., et al. (2018). The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br. J. Clin. Pharmacol. 84 (6), 1156–1169. doi:10.1111/bcp.13534
Wang, Y., Ma, Z., Liang, Q., Liu, M., Lu, B., Tan, H., et al. (2011). Study on the eighteen incompatible pairs based on cytochrome P450[J]. Mod. Traditional Chin. Med. Materia Medica-World Sci. Technol. (1):36–40.
Wu, X., Ma, J., Ye, Y., and Lin, G. (2016). Transporter modulation by Chinese herbal medicines and its mediated pharmacokinetic herb-drug interactions. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1026, 236–253. doi:10.1016/j.jchromb.2015.11.024
Xu, Z. Y., and Li, J. L. (2019). Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther. 12, 5467–5484. doi:10.2147/OTT.S194870
Yamazaki, M., Komizo, N., Iihara, H., Hirose, C., Yanase, K., Yamada, Y., et al. (2023). Relationship between osimertinib concentration and clinical response in Japanese patients with non-small cell lung cancer. Anticancer Res. 43 (2), 725–732. doi:10.21873/anticanres.16211
Yokota, H., Sato, K., Sakamoto, S., Okuda, Y., Fukuda, N., Asano, M., et al. (2022). Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. Invest New Drugs 40 (6), 1254–1262. doi:10.1007/s10637-022-01304-9
Yu, X., Xia, K., Wu, S., Wang, Q., Cheng, W., Ji, C., et al. (2022). Simultaneous determination and pharmacokinetic study of six components in beagle dog plasma by UPLC-MS/MS after oral administration of Astragalus membranaceus aqueous extract. Biomed. Chromatogr. 36 (12), e5488. doi:10.1002/bmc.5488
Keywords: osimertinib, traditional Chinese medicine (TCM), drug-drug interaction, non-small cell lung cancer, therapeutic drug monitoring
Citation: Zhang M, Ma H, Chen W and Yuan Z (2025) Potential interactions between traditional Chinese medicine and osimertinib: a Case Report. Front. Pharmacol. 16:1596913. doi: 10.3389/fphar.2025.1596913
Received: 20 March 2025; Accepted: 16 June 2025;
Published: 30 June 2025.
Edited by:
Seema Kumari, Dr. B.R Ambedkar University, IndiaReviewed by:
Teerapat Majam, Walailak University, ThailandRyan Varghese, Saint Joseph’s University, United States
Copyright © 2025 Zhang, Ma, Chen and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wanyi Chen, Y2hlbndhbnlpQGNxdS5lZHUuY24=; Zhongzhen Yuan, eXVhbnpob25nemhlbkBjcXUuZWR1LmNu
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work